Ion Beam Applications S.A. Overview
IBA describes itself as "the world leader in particle accelerator technology," and the description is substantively accurate in two niches: proton therapy, where it holds roughly 42% of the installed base of proton therapy rooms and sold 12 of the industry's new rooms in 2025, and cyclotrons for radiopharmaceutical production, where its Cyclone family spans every accelerator-produced isotope from F-18 to Astatine-211. Around these sit three adjacent franchises: Rhodotron/Dynamitron electron-beam and X-ray accelerators for medical-device sterilisation, radiation-therapy and imaging quality-assurance (Dosimetry), and an expanding nuclear-medicine "ventures" portfolio led by its equity stake in PanTera (Actinium-225). After a decade of thin margins, IBA is in a profitability turnaround: FY2025 revenue reached a record EUR 620 million, Proton Therapy returned to positive adjusted EBIT, and management targets around 10% adjusted EBIT margin by 2028. The investment case rests on converting a EUR 1.6 billion backlog profitably while capturing option value in alpha-emitter radioisotopes.
What IBA does
IBA designs, manufactures, installs and services particle accelerators and associated systems, and applies that technology in medicine and industry. Since FY2025 it reports in two segments plus a corporate/ventures layer:
IBA Clinical: Proton Therapy (Proteus®ONE and Proteus®PLUS systems, upgrades, restorations, and long-term operations & maintenance contracts) and Dosimetry (quality-assurance hardware and software for radiation therapy, proton therapy and medical imaging).
IBA Technologies: RadioPharma Solutions (RPS) (cyclotrons, targets, radiochemistry synthesisers including the newly acquired ORA NEPTIS® line, consumables, facility design) and Industrial Solutions (Rhodotron® and other electron-beam/X-ray accelerators for sterilisation, food irradiation and materials processing).
IBA Corporate / Ventures: equity-accounted or minority investments: PanTera (Ac-225 production, ~35% at end-2025, ~31% expected after the final Series A tranche), a multi-ion (carbon) accelerator venture (40%), mi2-factory (power semiconductors, 15%), and the newly created Ekalia joint venture with Framatome (Astatine-211).
The company's own description (paraphrased from FY2025/H1 2026 releases)
IBA presents itself as the leading supplier of equipment and services for proton therapy, which it positions as one of the most advanced radiotherapy modalities, and also for industrial sterilisation, radiopharmaceuticals and dosimetry. It emphasises its Louvain-la-Neuve base, roughly 2,300 employees and its B Corp certification. Strategically, the FY2025 presentation frames 2025 as an "inflection point" at which the group shifts toward recurring, profitable growth beyond project cyclicality.
Business and revenue model
| Revenue mix item (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
| Proton Therapy equipment | 89.4 | 202.7 |
| Proton Therapy services | 123.4 | 131.7 |
| Dosimetry net sales (product-dominated) | 65.9 | 65.7 |
| IBA Technologies equipment | 188.8 | 182.7 |
| IBA Technologies services | 34.8 | 42.1 |
| Group total net sales | 498.2 | 620.2 |
IBA's model is a capital-equipment-plus-annuity model. Large equipment contracts (a single Proteus®ONE room including multi-year maintenance typically sells for EUR 35–45 million in Europe, or USD 45–55 million in the US; a Cyclone® KIUBE cyclotron for EUR 2.5–5 million) are recognised over time on a percentage-of-completion basis. Each installed system then generates multi-year service revenue — PT operations & maintenance contracts that can run 10+ years, and annually invoiced service contracts in Technologies.
Source: IBA FY2025 results presentation (FY2024 restated for new segmentation). Segment totals include inter-segment eliminations (Clinical reported 395.3 vs PT+Dosimetry 400.0).
On this basis, explicitly identified service revenue (PT services + Technologies services) was EUR 173.8 million in FY2025, or ~28% of group sales, versus ~32% in FY2024 — the share fell because equipment conversion accelerated, not because services shrank (PT services +7%, Technologies services +21%). Subscription and licensing revenues are not separately disclosed and appear immaterial; software is embedded in Dosimetry and PT offerings.
Value-chain position and customers
| Customer type | Segment | Examples (disclosed) |
|---|---|---|
| Academic medical centres and cancer centres | Proton Therapy | MD Anderson (3 Proteus®ONE retrofit), Duke Health (2 Proteus®ONE), University of Pennsylvania, MGH (system restoration) |
| Public health systems / ministries | Proton Therapy | Spanish Ministry of Health (10-system order), IPO-Porto (Portugal's national PT centre) |
| Private / philanthropic hospital groups | Proton Therapy | MacKay Memorial Hospital (Taiwan), Fundação Severino Sombra (Brazil) |
| Radiotherapy and imaging departments | Dosimetry | Hospitals and OEM partners globally |
| Radiopharmacy networks and radiopharma developers | RadioPharma Solutions | Telix/RLS (4 KIUBE), Jubilant Radiopharma (5 KIUBE), SpectronRx, an unnamed global producer (12 KIUBE 300), IRE |
| Contract sterilisers and medical-device makers | Industrial Solutions | Not individually named in materials reviewed; Chinese X-ray contracts cited |
IBA sits at the OEM/system-integrator layer: it designs accelerators (cyclotrons, synchrocyclotrons, Rhodotrons), sources components (magnets, RF, gantries, imaging, third-party equipment — the reason for the IFRS 15 principal-treatment change), integrates, installs and services. In nuclear medicine it is moving downstream into radiochemistry (ORA acquisition), consumables, and via ventures into isotope supply (PanTera Ac-225; Ekalia At-211).
End-markets
Oncology (proton therapy; radioligand/targeted alpha therapy supply chain), diagnostic imaging (PET tracers, including neurology and cardiology "white spaces"), medical-device sterilisation (conversion from ethylene oxide and Cobalt-60 gamma to e-beam/X-ray), food irradiation/phytosanitary, polymer cross-linking, and emerging environmental applications (PFAS destruction R&D). Through mi2-factory, IBA has an indirect exposure to silicon-carbide power semiconductors.
Independent characterisation
IBA is best understood as a mid-cap, project-driven medtech capital-goods company whose earnings power has been structurally suppressed by legacy low-margin proton therapy contracts, inflation on fixed-price backlogs, and working-capital-heavy delivery of large public projects (Spain, China). The FY2025–H1 2026 data show the turnaround is real at the operating line (PT adjusted EBIT from -12.1 in FY2024 to +12.3 in H1 2026 alone) but cash conversion lags (operating cash flow negative in both FY2024 and FY2025; net debt rose to 81 at June 2026). Strategic optionality is disproportionately concentrated in nuclear medicine, where the RPS franchise and PanTera stake could be worth a substantial portion of the current market capitalisation.
Strategy
Stated strategy (themes from the Capital Markets Day framework reused in FY2025 and H1 2026 presentations)
IBA organises its strategy around three axes applied to each business unit, plus a ventures layer:
-
Increase technology penetration in core markets — in PT, via clinical evidence (MD Anderson Level 1 evidence; ASTRO model policy update placing oropharyngeal cancer in Group 1) and product innovation (DynamicARC®, ConformalFLASH®, AdaPTInsight XR); in Dosimetry, via a combined imaging + RT QA portfolio; in Industrial, via accelerator-based sterilisation replacing EtO and gamma; in RPS, via diagnostic "white spaces" (neurology, cardiology).
-
Expand in high-potential geographies — Asia (especially China), US leadership, emerging markets.
-
Expand along the value chain — PT service profitability and heavy-particle modalities; Dosimetry QA value-chain share via acquisitions (PhantomX) and partnerships; Industrial services and new applications (polymers, phytosanitary, PFAS); RPS theranostics (Ac-225, At-211) and radiochemistry/consumables (ORA, CASSY®).
-
Capital-light ventures — "additional growth via capital-light investments into new ventures (e.g., PanTera, mi2-factory)."
The RPS unit has articulated an explicit repositioning from equipment supplier to "precision oncology enabler" — integrated isotope supply, GMP manufacturing and CDMO-type partnerships with oncology centres.
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| New segmentation and IFRS 15 change | Mar 2025 | Clinical/Technologies structure; principal treatment of third-party equipment | Implemented |
| SAP S/4 ERP upgrade | 2025–H1 2026 | Group ERP migration (EUR 5.3 million one-off cost in FY2025; EUR 2.1 million in H1 2026) | Completion targeted H1 2026; invoicing delays noted |
| PanTera scale-up | 2025–2028 | Weekly Ac-225 production, cGMP recognition, commercial plant groundbreaking (Oct 2025), TerraPower/IRE expansion (May 2026) | New line end-2027; large-scale centre 2028 |
| ORA acquisition | Dec 2025 | Radiochemistry synthesisers; integration and portfolio optimisation under way | Integrating |
| PhantomX acquisition | 2,025 | AI-enabled QA phantoms for Dosimetry | Completed |
| Refinancing | 2,025 | EUR 125 million bank package (press release) / EUR 135 million total package incl. EUR 10 million subordinated loan (presentation) | Closed |
| Dosimetry cost programme | Mar 2026 | Reorganisation to realign cost base | Partial offset expected H2 2026 |
| Product launches | 2025–2026 | DynamicARC® MVP, CASSY®, myQA® Blue Phantom³, myQA® StarTrack³, AdaPTInsight XR, Rhodotron® LITE, Cyclone® iKure | Launched |
| Ekalia JV (At-211) with Framatome | Oct 2026 (MoU 2024–25) | International network of At-211 production sites; first site Nantes area by ~2028 | JV formed |
| Accelerate.EU | 2025–2026 | EU IHI project coordinated by IBA and Jules Bordet Institute; first At-211 pilot study in 2026 | Ongoing |
| Leadership transition | Jun 2026 | De Romrée operational lead; Legrain strategic steering | Implemented |
| Share buyback for LTIP | Feb–Jun 2026 | 400,000 shares | Completed |
Sustainability commitments
B Corp recertification (score 118), first CSRD report published, >90% renewable electricity, Scope 1 & 2 decarbonisation on track toward a net-zero operations target by 2030, ESG screening of >50% of spend, Oncia Community patient-support initiative.
Medium-term financial targets and guidance
| Target | Value | Status (as of Aug 2026) |
|---|---|---|
| FY2025 guidance: Group adjusted EBIT | ≥ EUR 25 million; PT adjusted EBIT positive | Delivered: EUR 27.4 million; PT EUR 10.2 million |
| FY2026 guidance: Group adjusted EBIT | ≥ EUR 32 million | Reiterated (May and Aug 2026); H1 2026 EUR 17.6 million |
| 2024–2028 revenue CAGR | 5–7%, front-loaded after high-growth period | Reiterated |
| OpEx | Up to 30% of sales p.a. | 28.7% in H1 2026 |
| Adjusted EBIT margin | ~10% of revenue by 2028 | 4.4% FY2025; 5.4% H1 2026 |
| Longer-term aspiration | ~40% gross margin and ~10% EBIT margin (per H1 2026 call summary on Investing.com; not in the press release) | Aspirational |
| Net financial position | Improve over 2027 | Net debt 81 at June 2026 |
Analyst arithmetic: 5–7% CAGR from FY2024's 498.2 implies FY2028 revenue of ~605–653; FY2025 already reached 620, so the outlook implies relatively flat-to-modest revenue in 2026–2028 with margin expansion doing the work. 10% of ~630 implies ~EUR 63 million adjusted EBIT by 2028.
Products & Services
IBA Clinical — Proton Therapy
| Product / service | Description and capabilities | Target customer | Launch / latest version | Pricing (if disclosed) |
|---|---|---|---|---|
| Proteus®ONE (brand of Proteus®235) | Compact single-room proton therapy solution built around a superconducting synchrocyclotron and compact gantry; pencil-beam scanning; image guidance; designed to integrate future upgrades. EU MDR certificate obtained for Proteus®235 in 2025 | Hospitals and cancer centres wanting a single-room or multi-room modular deployment | First clinical use ~2014 (not re-verified); continuously upgraded | EUR 35–45 million per system incl. multi-year maintenance (Europe/Asia/LatAm); USD 45–55 million in the US (2025–2026 releases) |
| Proteus®PLUS | Multi-room proton therapy centre based on the C235 isochronous cyclotron serving several gantry and fixed-beam rooms | Large academic and national centres | Long-standing platform; restoration offers for legacy sites | Not disclosed per contract |
| DynamicARC® | Proton arc therapy solution (rotational delivery) — minimum viable product launched in 2025; still described as in development | Existing and new Proteus users | MVP 2025 | — |
| ConformalFLASH® | Ultra-high dose-rate (FLASH) proton delivery; FDA Investigational Device Exemption approval for first-in-human trial obtained in H1 2026; research agreements with Kansas (KUMC) and others since 2023 | Research and academic centres | FDA IDE 2026 | — |
| AdaPTInsight XR | Imaging upgrade for adaptive proton therapy launched in H1 2026 | Installed base | 2,026 | — |
| System restoration / upgrades | Full-system restoration of legacy Proteus®PLUS sites to modern standards (first contract MGH, 2023; restoration begun 2025) | Ageing installed base | 2023–2025 | — |
| Operations & maintenance (O&M) | Multi-year service contracts; 7 renewals in 2025; PT services backlog EUR 784 million at end-2025 | All operating sites (45 at end-2025; 47 at mid-2026) | Ongoing | Embedded in system pricing |
China: IBA reports that NMPA clinical trials met all primary endpoints (H1 2026) and has a collaboration agreement with CGN Medical Technology; CGN appears in IBA's H1 2026 new-room market share chart via that collaboration.
IBA Clinical — Dosimetry
| Product / service | Description | Target customer | Latest version year |
|---|---|---|---|
| myQA® platform | Integrated QA software ecosystem linking detectors, phantoms and data management for RT, PT and imaging | Radiotherapy physics departments | Ongoing |
| myQA® Blue Phantom³ | Water-phantom beam scanning system for linac/proton beam commissioning | RT/PT physicists | 2025 release |
| myQA® StarTrack³ | Detector array for QA; released at ESTRO 2026 | RT physicists | 2,026 |
| Linac QA detector (fast, high-resolution) | New detector presented at a 2026 conference (per Q1 2026 update) | RT physicists | 2,026 |
| QUASAR® phantoms (Modus QA) | Anthropomorphic and motion phantoms; QUASAR® MR simulation phantom launched for RT market | RT and MR-sim users | QUASAR MR-sim 2025 |
| PhantomX phantoms | Acquired in 2025 to enable AI-based quality assurance | Imaging and RT QA | Acquisition 2025 |
| Proton therapy QA | Dedicated PT dosimetry tools; growing share of Dosimetry backlog | PT centres | Ongoing |
| Medical imaging QA | QA for diagnostic X-ray/CT; under competitive and pricing pressure | Imaging departments | Ongoing |
| IBA Dosimetry Academy / services | Training, calibration and service | All customers | Ongoing |
IBA Technologies — RadioPharma Solutions
| Product | Key specification (energy / beam current / last major redesign) | Use | Pricing |
|---|---|---|---|
| Cyclone® KEY | 9.2 MeV / 100 µA / 2022 | Compact, in-hospital F-18 and short-lived PET isotopes | — |
| Cyclone® KIUBE (180 / 300) | 18 MeV / 300 µA / 2016; KIUBE 300 can produce up to 35 Ci F-18 in a two-hour dual-beam run; fleet availability >97% (IBA) | High-volume PET radiopharmacies (F-18, Ga-68, Zr-89, C-11) | EUR 2.5–5 million depending on configuration |
| Cyclone® 30XP | 15–30 MeV / 500 µA / 2010 | Multi-particle research and SPECT/PET isotopes | — |
| Cyclone® 70 | 30–70 MeV / 750 µA / 2013 | High-energy isotope production (e.g., Sr-82, Ge-68) | — |
| Cyclone® IKON | 13–30 MeV / 1,500 µA / 2021 | High-energy, high-current industrial isotope production (installed at IRE, Belgium; ordered by PET Pharm Bio, Taiwan) | — |
| Cyclone® iKure | 28.5–29.5 MeV / 2 x 100 µA (alpha) / 2026 | Purpose-built for industrial-scale Astatine-211; launched at SNMMI 2026 | — |
| Nirta® targets (incl. HCFT) | Helium-cooling-free F-18 targets | Cyclotron users | Recent |
| NEPTIS® synthesisers (ORA) | Fully automated PET radiochemistry modules; ~600 units installed; NEPTIS® xSeed™ for method development, NEPTIS® NaF and others | PET drug manufacturers | Acquired Dec 2025 |
| CASSY® | New compact radiochemistry synthesiser platform launched 2025 | Radiopharmacies | 2,025 |
| Synthera® (legacy IBA radiochemistry) | Automated synthesis modules | Radiopharmacies | Legacy (portfolio optimisation with ORA under way) |
| IntegraLab® | Turnkey radiopharmacy facility design and integration | New production sites | Ongoing |
| Consumables and IBA Kare portal | Cassettes/reagent kits; online customer portal for KIUBE users | Installed base | Ongoing |
IBA Technologies — Industrial Solutions
| Product | Description | Target | Latest version |
|---|---|---|---|
| Rhodotron® (TT series) e-beam / X-ray | High-power, high-energy electron accelerators; X-ray conversion for pallet-scale sterilisation; first large-scale X-ray and the world's largest e-beam installations accepted in H1 2026 | Contract sterilisers, medical-device OEMs | Ongoing |
| Rhodotron® LITE | Lower-power X-ray Rhodotron, dual 5/7 MeV, competitive with 1–1.5 MCi gamma centres, aimed at gamma operators, new entrants and in-house sterilisation | Smaller sterilisation sites, food irradiation | Launched 2026 |
| Dynamitron® / low-energy e-beam | Lower-energy electron accelerators for materials processing | Polymer/cable/industrial users | Legacy line (details not re-verified) |
| Rhodotron® for isotopes | Rhodotron used by PanTera for photonuclear Ac-225 production from Ra-226 | Isotope producers | Ongoing |
| Customer Care / services ("Beyond™" brand on IBA Industrial site) | Service, upgrades, uptime programmes | Installed base | Ongoing |
| New applications R&D | PFAS destruction ("PFAS-Blaster"), polymer modification pilots, phytosanitary treatment | Environmental/industrial | Development stage |
Financial Narrative
Basis warning: FY2021–FY2022 are on the pre-IFRS 15 change basis; FY2023 is restated (466.7) — original reported FY2023 revenue was 428.7. Adjusted EBIT = REBIT for earlier years.
Income statement
Sources: FY2022 release (FY2021–22 sales, gross margin 34.4%/35.1%, REBIT, net result); FY2023 release (REBIT, REBITDA 19.3 on original 428.7 basis, net result); FY2024 release (restated FY2023 revenue 466.7); FY2025 release/presentation. FY2021 gross profit and FY2021 REBITDA derived from disclosed margins (34.4% and 7.9%); FY2022 gross profit derived from 35.1%. FY2021–FY2022 EPS derived from net result / ~29.1–29.2 million weighted shares (analyst estimate); FY2023 EPS per Digrin aggregator. FY2021 dividend derived (FY2022 EUR 0.21 described as +10%). FY2023 dividend EUR 0.17 per 2024 AGM notice; FY2024 EUR 0.24 per 2025 AGM notice; FY2025 EUR 0.25 per 2026 AGM notice. Diluted EPS is not disclosed in the materials reviewed and is assumed close to basic given limited dilution.
Margins and growth
FY2023 growth (18.7%) is on the original basis (428.7 vs 361.3). FY2023 adjusted EBITDA margin computed on restated revenue (19.3/466.7). Discrepancy: the FY2024 release reported FY2024 gross margin of 33.3%; the FY2025 presentation shows restated FY2024 gross margin of 33.7% (new segmentation restatement).
Revenue CAGR: FY2021–FY2025 ≈ 18.6% p.a. (mixed accounting basis — overstated by the IFRS 15 change); FY2023R–FY2025 ≈ 15.3% p.a. (like-for-like basis).
Commentary. Revenue nearly doubled over four years, driven first by Other Accelerators (Industrial + RPS) in 2022–2024 (sterilisation capacity investment post-COVID; RPS growth) and then by Proton Therapy backlog conversion in 2025 (PT sales +57%, nine rooms delivered). Margin progression has been non-linear. The FY2023 trough reflected three PT-specific issues the company explicitly cited: delays converting Proteus®PLUS projects in China, a mix of older low-margin contracts, and inflation/FX on fixed-price backlog. Gross margin has trended down from ~35% (FY2022) to 32.2% (FY2025), partly mechanically (IFRS 15 grossing-up of third-party equipment depresses percentage margins) and partly due to legacy low-margin PT projects. The H1 2026 gross margin recovery to 33.7% (vs 29.5% in H1 2025) is the first clear evidence that newer, better-priced PT contracts and service scale are flowing through. Operating leverage is the dominant profit driver: OpEx grew 14% in FY2025 against 24% revenue growth, falling to 28% of sales, within the ≤30% framework.
Interim P&L (latest)
Source: IBA H1 2026 presentation appendix. H1 2025 EPS derived (analyst). Below-adjusted-EBIT items in H1 2026: ERP upgrade -2.1, Dosimetry restructuring -1.6, other -1.1; forex -1.0; Argentina hyperinflation impact on Buenos Aires PT project.
Bridge from Adjusted EBIT to net profit, FY2025
Source: FY2025 presentation (figures as presented; minor rounding). Analyst note: ~EUR 7.2 million of FY2025 pre-tax profit was a non-cash revaluation gain on PanTera — underlying net profit excluding it would have been materially lower.
Balance sheet
Sources: FY2025 presentation (FY2024–25 balance sheets); FY2022 and FY2023 results releases (gross and net cash); FY2023 total assets and equity from Google Finance aggregator. Company "net working capital" (operating definition) was -89 (2023), -64 (2024), -21 (2025) per H1 2026 presentation.
Commentary. The defining balance-sheet trend is the erosion of IBA's historical net cash (117 at end-2022) into net debt (58 at end-2025; 81 at mid-2026). This is not driven by losses but by working capital: advance billings (contract liabilities) have unwound from ~298 to ~218 as large projects matured, while contract assets and inventories grew with the Spanish (10-system) and Chinese PT projects. The H1 2026 increase was amplified by IBA's SAP S/4 ERP migration, which changed how procurement progress is recognised (equipment held in inventory until later allocation; ~EUR 50 million of offsetting accruals in payables) and temporarily delayed invoicing. Management expects improvement from H2 2026 with acceleration in 2027 as Spanish deliveries advance. Equity remains thin relative to the balance sheet (equity/assets ~16% at mid-2026), and goodwill/intangibles rose with ORA and PhantomX.
Cash flow
Sources: FY2025 presentation; FY2023 OCF from Google Finance aggregator.
Commentary. Cash generation before working capital is improving in line with EBITDA (30.1 in FY2025 vs 17.8 in FY2024), but has been entirely absorbed by working-capital build. Free cash flow has been negative for two consecutive years. Capex is modest (~2% of sales), confirming an asset-light manufacturing model; the "capital-light" stance extends to ventures, which are funded via third-party equity (PanTera Series A) rather than IBA's balance sheet.
Key ratios
All ratios are analyst calculations from IBA disclosures except the company net leverage ratio. Cash conversion cycle not publicly disclosed. Company net leverage ratio rose to 1.14x at 30 June 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Business units | Contents |
|---|---|---|
IBA Clinical | Proton Therapy; Dosimetry | Proteus®ONE, Proteus®PLUS, upgrades (DynamicARC®, ConformalFLASH®, AdaPTInsight), restorations, O&M services; myQA® platform, phantoms (incl. QUASAR® via Modus QA), imaging QA, PhantomX AI-QA phantoms |
IBA Technologies | RadioPharma Solutions; Industrial Solutions | Cyclone® KEY/KIUBE/30XP/70/IKON/iKure cyclotrons, Nirta® targets, Synthera/CASSY®/NEPTIS® radiochemistry, consumables, IntegraLab® design; Rhodotron® e-beam/X-ray (incl. Rhodotron® LITE), services |
Corporate / Ventures | n/a (not a reporting segment) | Group costs; equity-accounted PanTera; minority venture stakes |
Segment net sales (EUR Mn)
| Segment net sales (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
IBA Clinical | 274.6 | 395.3 |
IBA Technologies | 223.5 | 224.9 |
Group total | 498.2 | 620.2 |
Business-unit net sales (EUR Mn)
| Business-unit net sales (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Proton Therapy | 212.8 | 334.3 |
Dosimetry | 65.9 | 65.7 |
IBA Technologies (RPS + Industrial combined) | 223.5 | 224.9 |
Adjusted EBIT (EUR Mn)
| Adjusted EBIT (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Proton Therapy | -12.1 | 10.2 |
Dosimetry | 4.1 | 2.6 |
IBA Technologies | 30.6 | 20.0 |
Corporate / eliminations (derived) | -5.3 | -5.4 |
Group Adjusted EBIT | 17.3 | 27.4 |
Adjusted EBIT margin (%)
| Adjusted EBIT margin (%) | FY2024 | FY2025 |
|---|---|---|
Proton Therapy | -5.7 | 3.0 |
Dosimetry | 6.2 | 3.9 |
IBA Technologies | 13.7 | 8.9 |
Group | 3.5 | 4.4 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | FY2024 | FY2025 |
|---|---|---|
IBA Clinical share of group sales | 55.1 | 63.7 |
IBA Technologies share of group sales | 44.9 | 36.3 |
IBA Clinical YoY growth | — | 44 |
IBA Technologies YoY growth | — | 1 |
Proton Therapy YoY growth | — | 57 |
Dosimetry YoY growth | 0 | 0 |
Revenue by Segment
| Segment metric (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
IBA Clinical net sales | 189.5 | 196.8 |
Proton Therapy net sales | 154.8 | 167.7 |
— PT equipment | 90.8 | 101.7 |
— PT services | 64.0 | 66.0 |
Dosimetry net sales | 34.8 | 30.8 |
IBA Technologies net sales | 115.4 | 127.0 |
— Technologies equipment | 95.5 | 106.6 |
— Technologies services | 19.9 | 20.3 |
PT Adjusted EBIT | -2.2 | 12.3 |
Dosimetry Adjusted EBIT | 2.3 | -0.5 |
Technologies Adjusted EBIT | 13.1 | 8.2 |
Group Adjusted EBIT | 10.6 | 17.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansInterim margin (%)
| Interim margin (%) | H1 2025 | H1 2026 |
|---|---|---|
PT Adjusted EBIT margin | -1.4 | 7.3 |
Dosimetry Adjusted EBIT margin | 6.5 | -1.7 |
Technologies Adjusted EBIT margin | 11.3 | 6.5 |
Revenue by Segment (Annual)
| Old-basis metric (EUR Mn) | FY2023 | FY2024 |
|---|---|---|
Proton Therapy net sales (old perimeter, IFRS 15 restated) | 239.6 | 242.1 |
Proton Therapy REBIT | -23.4 | -21.5 |
Dosimetry net sales | 65.9 | 65.9 |
Dosimetry REBIT | 6.1 | 4.1 |
Revenue by Segment (FY2021–FY2025)
| Equipment order intake (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Proton Therapy | 141 | 281 | 117 | 106 | 250 |
Dosimetry | 50 | 67 | 67 | 66 | 60 |
IBA Technologies | 87 | 175 | 104 | 149 | 142 |
Group total | 278 | 523 | 288 | 321 | 452 |
Revenue by Segment by Equipment Order Intake
| Equipment order intake (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Proton Therapy | 23 | 112 |
Dosimetry | 31 | 36 |
IBA Technologies | 53 | 28 |
Group total | 107 | 176 |
Income statement (EUR Mn)
| Income statement (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 313.0 | 361.3 | 466.7 | 498.2 | 620.2 |
Gross profit | 107.7 | 126.8 | — | 168.1 | 199.6 |
Operating expenses (S&M + G&A + R&D) | — | — | — | 150.8 | 172.2 |
Adjusted EBIT (REBIT) | 14.5 | 11.1 | 6.4 | 17.3 | 27.4 |
Adjusted EBITDA (REBITDA) | 24.7 | 21.6 | 19.3 | 32.0 | 49.4 |
Profit before tax | — | — | — | 14.9 | 18.8 |
Net result | 3.9 | 6.1 | -9.1 | 9.3 | 12.7 |
EPS basic (EUR) | 0.13 | 0.21 | -0.31 | 0.32 | 0.43 |
Dividend per share for the year (EUR, gross) | 0.19 | 0.21 | 0.17 | 0.24 | 0.25 |
Margin / growth (%)
| Margin / growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 34.4 | 35.1 | — | 33.7 | 32.2 |
Adjusted EBIT margin | 4.6 | 3.1 | 1.4 | 3.5 | 4.4 |
Adjusted EBITDA margin | 7.9 | 6.0 | 4.1 | 6.4 | 8.0 |
Net margin | 1.2 | 1.7 | -2.0 | 1.9 | 2.1 |
Revenue growth YoY | — | 15.4 | 18.7 | 6.7 | 24.5 |
OpEx as % of sales | — | — | — | 30.3 | 27.8 |
Income Statement and Margin Analysis (%)
| Interim P&L (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Revenue | 304.9 | 323.7 |
Gross profit | 90.0 | 108.9 |
Selling & marketing | 15.9 | 17.0 |
General & administrative | 32.3 | 39.4 |
Research & development | 31.2 | 36.4 |
Adjusted EBIT | 10.6 | 17.6 |
Reported EBIT | 7.0 | 12.8 |
Adjusted EBITDA | 16.4 | 26.6 |
Financial result | -5.0 | -2.6 |
Share of equity-accounted results | -0.8 | 2.1 |
Profit before tax | 1.2 | 12.3 |
Tax | -3.8 | -3.0 |
Net result | -2.6 | 9.3 |
EPS basic (EUR) | -0.09 | 0.32 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Item (EUR Mn) | FY2025 |
|---|---|
Adjusted EBIT | 27.4 |
ERP upgrade implementation | -5.3 |
Other operating result | 0.7 |
Other items | -1.2 |
PanTera revaluation gain | 7.2 |
Equity method result (PanTera) | -0.9 |
Financial result (incl. forex -3.3, Argentina -1.9/-1.7, interest/other -1.6) | -8.4 |
Profit before tax | 18.8 |
Tax | -6.0 |
Net profit | 12.7 |
Balance Sheet
| Balance sheet (EUR Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | — | 597.5 | 616.1 | 690.6 |
Cash and cash equivalents | 158.0 | 109.3 | 72.2 | 64.7 |
Short-term borrowings + current financial debts | — | — | 11.5 | 32.2 |
Long-term borrowings | — | — | 3.5 | 55.3 |
Lease liabilities (current + non-current) | — | — | 28.7 | 29.3 |
Net debt (negative = net cash), company definition | -117.0 | -67.7 | -33.5 | 58.0 |
Total equity | — | 106.2 | 110.9 | 127.2 |
Goodwill and other intangibles | — | — | 25.7 | 43.1 |
Inventories | — | — | 152.8 | 135.4 |
Contract assets | — | — | 77.0 | 113.3 |
Contract liabilities (advance billing) | — | — | 298.4 | 234.1 |
Working capital (current assets – current liabilities) | — | — | -21.3 | -3.1 |
Balance Sheet (FY2025–H1 2026)
| Interim balance sheet (EUR Mn) | FY2025 | H1 2026 |
|---|---|---|
Total assets | 690.6 | 753.9 |
Cash and cash equivalents | 64.7 | 43.6 |
Current borrowings | 32.2 | 29.7 |
Non-current borrowings | 55.3 | 60.1 |
Net debt (company) | 58.0 | 81.0 |
Equity | 127.2 | 119.2 |
Inventories | 135.4 | 167.2 |
Contract assets | 113.3 | 148.9 |
Trade payables | 119.9 | 179.2 |
Contract liabilities | 234.1 | 217.9 |
Cash flow (EUR Mn)
| Cash flow (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Net cash flow before working capital | — | 17.8 | 30.1 |
Change in working capital | — | -25.5 | -52.9 |
Operating cash flow | 12.0 | -10.6 | -25.7 |
Capital expenditure | — | -7.4 | -12.7 |
Free cash flow (OCF + capex) | — | -18.0 | -38.4 |
M&A and other investing | — | -6.4 | -22.6 |
Dividends paid | — | -4.9 | -7.1 |
Treasury share purchases | — | — | -6.3 |
Net borrowing / (repayment) | — | -3.7 | 76.3 |
Interim cash flow (EUR Mn)
| Interim cash flow (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Net cash flow before working capital | 7.4 | 18.2 |
Change in working capital | -43.1 | -25.6 |
Operating cash flow | -37.3 | -7.1 |
Capital expenditure | -5.2 | -4.3 |
M&A and other investing | -7.4 | -3.1 |
Net borrowing | 27.3 | 2.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%; net result / average equity) | — | 10.7 |
ROA (%; net result / average total assets) | — | 1.9 |
ROIC (%; analyst estimate: adj. EBIT after 32% effective tax / (equity + net debt)) | — | 10.1 |
Current ratio (x) | 0.95 | 0.99 |
Debt (incl. leases) / equity (x) | 0.39 | 0.92 |
Net debt / adjusted EBITDA (x; reported net debt) | — | 1.17 |
Company net leverage ratio (net senior debt / LTM adj. EBITDA, x) | — | 0.83 |
Interest coverage (adj. EBIT / bank interest & other, approx., x) | — | 17 |
Asset turnover (x; revenue / average assets) | — | 0.95 |
Geographic Revenue
| Region (% of group equipment order intake, excl. upgrades) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Americas | 41 | 26 | 45 | 55 | 27 |
EMEA | 19 | 56 | 43 | 20 | 30 |
APAC | 40 | 18 | 13 | 25 | 44 |
Geographic Revenue (FY2025–H1 2026)
| Proton Therapy sites | FY2025 | H1 2026 |
|---|---|---|
Americas — operating | 17 | 19 |
Americas — in installation | 3 | 5 |
Americas — in production | 7 | 6 |
EMEA — operating | 17 | 17 |
EMEA — in installation | 2 | 3 |
EMEA — in production | 14 | 15 |
APAC — operating | 11 | 11 |
APAC — in installation | 3 | 3 |
APAC — in production | 14 | 14 |
Total sites | 88 | 93 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price (16 Oct 2026) | EUR 16.44 | Zonebourse/TradingSat |
52-week range (as of Aug 2026) | EUR 9.90 – 17.76 | Google Finance |
Market capitalisation | ~EUR 498 million | Analyst calculation |
Average daily volume | ~28,000 shares (Aug 2026) | Google Finance |
Free float (unnotified) | ~42% of shares | IBA structure (Nov 2025) |
Reference prices (EUR) | Date | Price |
Buyback trades | 9–13 Feb 2026 | 15.20 average |
Buyback trade | 27 Mar 2026 (FY2025 results day) | 12.78 average |
Block purchase | 8 Jun 2026 | 16.34 |
Close | 3 Aug 2026 | 15.94 |
Close | 16 Oct 2026 | 16.44 |
Valuation Multiples
| Multiple | IBA | Basis |
|---|---|---|
P/E (trailing) | ~20x | Price 16.44 / TTM EPS ~0.80–0.84 (FY2025 0.43 + H1 2026 0.32 – H1 2025 -0.09) |
EV / Sales (trailing) | ~0.9x | EV ~579 (market cap 498 + net debt 81) / TTM revenue ~639 |
EV / Adj. EBITDA (trailing) | ~9.7x | TTM adj. EBITDA ~59.6 |
EV / FY2026 guided Adj. EBIT | ~18x | ≥32 guidance |
P/B | ~4.2x | Equity 119.2 (June 2026) |
Dividend yield | ~1.5% | EUR 0.25 / 16.44 |
Dividend per share (EUR, gross, by fiscal year)
| Dividend per share (EUR, gross, by fiscal year) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share | 0.19 | 0.21 | 0.17 | 0.24 | 0.25 |
Capital Programmes
| Programme | Period | Size | Purpose | Status |
|---|---|---|---|---|
2026 buyback | 3 Feb – 30 Sep 2026 | Up to 400,000 shares (~1.3% of shares) | Cover LTIP obligations | Completed 12 Jun 2026 (400,000 shares) |
Debt Facilities
| Facility (EUR Mn) | Committed | Drawn at 31 Dec 2025 |
|---|---|---|
Subordinated loan | 10 | 10 |
Bank 5-year term loan | 50 | 30 |
Bank acquisition term loan | 15 | 15 |
Revolving credit facilities | 60 | 25 |
Total package | 135 | 80 |
Analyst Conclusions
Management guidance
-
FY2026 Group adjusted EBIT of at least EUR 32 million (reiterated 27 August 2026; H1 delivered 17.6, implying ≥14.4 in H2).
-
2024–2028: revenue CAGR 5–7% (front-loaded), OpEx ≤30% of sales, adjusted EBIT margin ~10% by 2028.
-
Net financial position to improve over 2027 as Spanish PT deliveries progress.
-
Dosimetry cost measures to partially offset headwinds in H2 2026.
Consensus expectations
The single aggregator data point (three analysts, ~USD 21.7 target) implies modest upside; management guidance (≥32 EBIT for FY2026) is the anchor most brokers reference.
Bull case (grounded in data)
-
Margin convergence to ~10%: PT already at 7.3% adjusted EBIT margin in H1 2026 with gross margin up 4.1 points; if group revenue holds ~EUR 630–650 million and margin reaches 10% by 2028, adjusted EBIT roughly doubles from FY2025.
-
Nuclear-medicine re-rating: RPS momentum (12-unit KIUBE order, Telix, Jubilant), ORA consumables, Ekalia, and a PanTera stake worth ~EUR 90–100 million at last funding marks could be worth a large share of IBA's ~EUR 500 million market cap.
-
PT demand inflection from evidence: Lancet Level 1 data and ASTRO policy change support US reimbursement; 2025 was IBA's second-best year ever for rooms sold (12), and H1 2026 PT orders quadrupled (EUR 112 million vs 23).
Bear case (grounded in data)
-
Cash, not profit, is the binding constraint: FCF negative for two years; net debt rose from 58 to 81 in six months; any slippage in Spanish milestones extends the squeeze.
-
Order share erosion and lumpy intake: IBA's share of new PT rooms fell to 31% in H1 2026; two-year book-to-bill slid to 0.9x; Technologies book-to-bill 0.7x with Industrial orders depressed until ~2028–29.
-
Earnings quality and execution: recurring "one-offs" (ERP, restructuring, FX, Argentina), reliance on PanTera revaluation gains in FY2025, and Dosimetry losses suggest reported net profit will lag adjusted EBIT.
Key catalysts and monitorables (next 12 months)
| Date / timing | Catalyst | What to watch |
|---|---|---|
| 26 Nov 2026 | Q3 2026 business update | Net debt trajectory post-ERP; Q3 order intake; Dosimetry |
| H2 2026 | PanTera fourth Series A tranche | Valuation mark vs ~EUR 290 million; IBA stake ~31% |
| H2 2026–2027 | Spanish PT delivery milestones | Working-capital release |
| 18 Mar 2027 | FY2026 results | Delivery vs ≥EUR 32 million; FY2027 guidance; dividend |
| 2,027 | Ekalia site permitting/build; Accelerate.EU At-211 pilot | Alpha franchise de-risking |
| Ongoing | US PT orders following ASTRO update; DynamicARC®/ConformalFLASH® progress | Order share recovery |
| Ongoing | Industrial order recovery; Rhodotron® LITE first orders | Technologies book-to-bill |
| End-2027 / 2028 | PanTera new line; large-scale Actinium Production Center | Venture value crystallisation |
Analyst verdict
IBA has crossed the most important threshold in its recent history: Proton Therapy, the franchise that defined and long depressed the company, is now profitable on a sustained basis. The evidence is not just the FY2025 swing to EUR 10.2 million adjusted EBIT, but H1 2026's EUR 12.3 million at a 7.3% margin with a recovering gross margin of 33.7% — the signature of legacy contracts rolling off and a 47-site service base gaining scale. Combined with the strongest clinical-evidence tailwind the modality has ever had, the PT franchise now looks like a credible cash generator rather than a perennial drag.
The equity story, however, is no longer only about PT. The most asymmetric value sits in nuclear medicine: a cyclotron range that now reaches industrial At-211, a radiochemistry layer via ORA, and minority stakes in PanTera and Ekalia that are funded largely by partners. At roughly 0.9x EV/sales and ~10x trailing EBITDA, the market is ascribing limited value to these options.
Against this, the balance sheet has turned from a defensive asset into a constraint. Net debt of EUR 81 million is modest in absolute terms, but two years of negative free cash flow, ERP disruption and dependence on milestone timing on large public projects mean that cash conversion — not EBIT — is the variable investors should underwrite. Dosimetry and Industrial Solutions also need to stabilise before margin targets look secure.
On balance, IBA screens as a self-help turnaround with embedded radiopharma optionality. The thesis strengthens materially if FY2026 delivers at least EUR 32 million adjusted EBIT alongside visible net-debt reduction in H2 2026–2027; it weakens if book-to-bill stays below 1.0x and PT share in new rooms fails to recover. Our stance is constructive, conditional on cash delivery.
All derived figures are labelled as analyst calculations.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / recent change | Prior roles / notes | Age / education |
|---|---|---|---|---|
Olivier Legrain | Chief Executive Officer; Vice-Chairman of the Board (since June 2026) | CEO since May 2012; previously Chief Strategy Officer and COO (Jan 2012) | Has led IBA through the PT build-out, the 2023 trough and the 2025 turnaround; now focused on strategic steering | Not disclosed in materials reviewed |
Henri de Romrée | Deputy CEO; strategic and operational responsibility for all Group activities (since June 2026) | Deputy CEO since March 2024; previously led IBA Technologies | — | — |
Catherine Vandenborre | Chief Ventures & Corporate Officer (since June 2026); leads partnerships, innovation and cross-functional departments including Finance | CFO and "IBA Corporate Lead" at FY2025 results (March 2026) | — | — |
Christian Matton | Chief Legal Officer | Secretary of 2025 AGM | — | — |
Loïk-Maël Nys | President, IBA RadioPharma Solutions | Quoted as President in October 2026 KIUBE release | Succeeded Charles Kumps (President RPS through at least March 2026); succession date not disclosed | — |
Thomas Pevenage | Head of Investor Relations | — | — | — |
Olivier Lechien | Corporate Communication | — | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Notes |
|---|---|---|
Saint-Denis SA, represented by Pierre Mottet | Chairman | Chairman since 2013 (per succession plan); former IBA CEO (24 years at IBA by 2012) |
Olivier Legrain | Vice-Chairman; executive director (CEO) | Appointed Vice-Chairman June 2026 |
Joyce Hansen | Director (joined June 2026) | ~Four decades in industrial microbiology and sterility assurance (Johnson & Johnson) |
Dr Stephen Hahn | Director (joined June 2026) | Physician-scientist; former US FDA Commissioner; CEO and Board Chair of Nucleus RadioPharma |
Christine Dubus | Independent director; Audit Committee chair (as appointed 2020) | — |
Dr Richard Hausmann | Independent director (appointed 2020) | — |
Three directors proposed by the IBA Foundation (private trust) | Directors | — |
Departed (June 2026) | Sybille van den Hove (chair of Sustainability Board since its creation); Muriel de Lathouwer | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
March 2024 | Henri de Romrée appointed Deputy CEO | Focus on Other Accelerators performance and future opportunities |
~April 2025 | CFO Soumya Chandramouli departs (to Novadip) | Catherine Vandenborre subsequently CFO |
16–17 June 2026 | Joyce Hansen and Stephen Hahn join; van den Hove and de Lathouwer leave | Adds sterilisation and FDA/radiopharma expertise |
17 June 2026 | Legrain Vice-Chairman; de Romrée full operational responsibility; Vandenborre Chief Ventures & Corporate Officer | Presented as a prepared leadership transition; effectively sets up de Romrée as operational successor |
2026 (by October) | Loïk-Maël Nys becomes President of RPS | Replaces Charles Kumps (date not disclosed) |
Major Shareholders
| Holder | Shares | % of shares | % of voting rights |
|---|---|---|---|
Sustainable Anchorage SRL (anchor/founder-management vehicle, formerly Belgian Anchorage) | 6,204,668 | 20.49 | 30.48 |
Premier Miton Capital | 1,815,605 | 6.00 | 4.48 |
Vallcara Limited | 1,621,565 | 5.35 | 4.00 |
Institut des Radioéléments (IRE) | 1,423,271 | 4.70 | 7.03 |
Belfius Insurance | 1,189,196 | 3.93 | 5.87 |
IBA SA (treasury) | 962,329 | 3.18 | 2.54 |
Paladin Asset Management | 806,569 | 2.66 | 1.99 |
Wallonie Entreprendre | 715,491 | 2.36 | 3.53 |
FMR LLC (Fidelity) | 579,650 | 1.91 | 1.43 |
NS Partners Europe SA | 437,748 | 1.45 | 1.08 |
UCLouvain | 426,885 | 1.41 | 2.11 |
BNP Paribas Asset Management | 407,985 | 1.35 | 1.01 |
Bayrime SA | 265,937 | 0.88 | 0.66 |
Public / free float (unnotified) | 12,583,711 | 41.55 | 31.58 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs IBA |
|---|---|---|
Proton therapy | Varian (Siemens Healthineers) — ProBeam® | #2 installed base (~21–22%); deep RT/linac channel and software; stronger balance sheet |
Proton therapy | Hitachi | ~19% installed base; ~11% of 2025 new rooms; strong in Japan/US academic |
Proton therapy | Mevion Medical Systems | ~9% installed base; compact single-room; 21% of 2025 and 31% of H1 2026 new rooms; private |
Proton therapy | Sumitomo Heavy Industries | Asia-focused proton systems; included in "others" |
Proton therapy | ProTom International | 5% of 2025 new rooms (Radiance 330) |
Proton therapy | CGN Medical Technology | 19% of H1 2026 new rooms (counted via collaboration agreement with IBA, per IBA footnote) |
Proton therapy / heavy ion | Toshiba Energy Systems, Hitachi (carbon) | Carbon-ion competition to IBA's multi-ion venture |
Cyclotrons (RPS) | GE HealthCare (PETtrace) | Major installed base in PET cyclotrons |
Cyclotrons (RPS) | Siemens Healthineers (Eclipse) | PET cyclotron and radiopharmacy network synergies |
Cyclotrons (RPS) | Sumitomo Heavy Industries | HM-series cyclotrons, strong in Asia |
Cyclotrons (RPS) | Best Cyclotron Systems (TeamBest), ACSI | High-energy and medium cyclotrons |
Radiochemistry | GE HealthCare (FASTlab), Trasis, Eckert & Ziegler | Synthesiser competition to NEPTIS®/CASSY® |
Industrial sterilisation equipment | Mevex, Wasik Associates, NHV Corporation, others | E-beam/X-ray accelerator OEMs; gamma (Cobalt-60) and EtO are substitute technologies |
Dosimetry | Sun Nuclear (Mirion Medical) | Leading RT QA competitor |
Dosimetry | PTW Freiburg, Standard Imaging, LAP | Detectors, phantoms, QA software |
Competitor Detail
| Proton therapy installed-room share (%) | H1 2026 |
|---|---|
IBA | 42 |
Varian | 21 |
Hitachi | 19 |
Mevion | 9 |
Others | 9 |
Share of new PT rooms sold (%) | FY2024 |
IBA | 56 |
Mevion | 44 |
Hitachi | 0 |
ProTom | 0 |
CGN (via IBA collaboration) | 0 |
Peer Comparison FY2025
| Metric | IBA (FY2025, EUR) | Siemens Healthineers — Varian segment (FY Sep-2025, EUR) | Mirion Technologies — Medical segment (FY2025, USD) |
|---|---|---|---|
Revenue | 620.2 M | 4,081 M | 310.8 M (group 925.4 M) |
Revenue growth | +24% | +6.9% | +3.7% (group +7.5%) |
Margin | Adj. EBIT 4.4% | Adj. EBIT margin 13.2–19.7% across FY2025 quarters (Q4: 19.7%) | Operating income 46.9 M (~15.1%) |
R&D intensity | 10.0% of sales | Not disclosed at segment level | Not disclosed at segment level |



